It looks like as far as preliminary results go for planning a resource flow test, Grandis couldnt really get much better. I dont know alot about this kind of thing at the depths and targets but I think there is some real confidence within the team. It all rests on Gragory Channon who to me appears to be quite the expert in his videos.
Sounds like we will know a bit sooner than we all expected. With any good flow test results probably going to be advertised quite strongly by NY and then it will be a little wait for certifiers to acknowledge and cement the numbers. If its good, I hope we get SP appreciation between those two events.
- Forums
- ASX - By Stock
- EXR
- General chit chat thread.
General chit chat thread., page-3150
-
- There are more pages in this discussion • 623 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
SKS
SKS Technologies wins US$90M award to supply power to international hyperscale data centre in Melbourne
RNU
Renascor wins a funding boost given it wants to produce a critical mineral – but $5M award pales in comparison to some
Add EXR (ASX) to my watchlist
(20min delay)
|
|||||
Last
12.5¢ |
Change
0.010(8.70%) |
Mkt cap ! $141.7M |
Open | High | Low | Value | Volume |
12.0¢ | 13.0¢ | 11.3¢ | $227.7K | 1.882M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 199999 | 12.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
13.0¢ | 453173 | 11 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 199999 | 0.125 |
2 | 115000 | 0.120 |
2 | 61188 | 0.115 |
13 | 362373 | 0.110 |
6 | 95889 | 0.105 |
Price($) | Vol. | No. |
---|---|---|
0.130 | 323173 | 8 |
0.135 | 121000 | 4 |
0.140 | 176835 | 9 |
0.145 | 42600 | 3 |
0.150 | 285811 | 5 |
Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
Featured News
SKS
SKS Technologies wins US$90M award to supply power to international hyperscale data centre in Melbourne
TLX
Telix jumps 11.6% as US government indicates proposed medicare changes won't affect prostate cancer drug
EXR (ASX) Chart |